Absence of epidermal growth factor receptor mutations in cervical cancer

International Journal of Gynecological Cancer

Volumn 18, Issue 4, 2008, Pages 749-754

  Arias Pulido, H ^a   Joste, N ^a   Chavez, A ^a   Muller, C Y ^a   Dai, D ^a   Smith, H O ^a   Verschraegen, C F ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Cervical cancer; EGFR; Mutation analysis; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GLOBIN GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HELA CELLS; HUMANS; LUNG NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 47649119001     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01111.x     Document Type: Article

References (48)

1. Vizcaino A, Moreno V, Bosch F et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000 86 : 429 35.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006 56 : 106 30.
3. Jemal A, Clegg L, Ward E et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004 101 : 3 27.
4. Green J, Kirwan J, Tierney J et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005 : CD002225.
5. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003 30 (Suppl. 7 3 14.
6. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005 23 : 2445 59.
7. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 : 2129 39.
8. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 : 1497 500.
9. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 101 : 13306 11.
10. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005 23 : 2556 68.
11. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006 118 : 209 14.
12. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004 64 : 7241 4.
13. Sordella R, Bell D, Haber D, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004 305 : 1163 7.
14. Kersemaekers AM, Fleuren GJ, Kenter GG et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999 5 : 577 86.
15. Kim GE, Kim YB, Cho NH et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 2004 10 : 1366 74.
16. Lee C, Lee R, Hammond E et al. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 2004 93 : 209 14.
17. Gaffney DK, Haslam D, Tsodikov A et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003 56 : 922 8.
18. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993 46 : 149 53.
19. Kristensen GB, Holm R, Abeler VM, Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996 78 : 433 40.
20. Lee CM, Shrieve DC, Zempolich KA et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005 99 : 415 21.
21. Maruo T, Yamasaki M, Ladines-Llave CA, Mochizuki M. Immunohistochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. Cancer 1992 69 : 1182 7.
22. Pfeiffer D, Stellwag B, Pfeiffer A, Borlinghaus P, Meier W, Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1989 33 : 146 50.
23. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001 61 : 249 55.
24. Narayan G, Arias-Pulido H, Koul S et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2003 2 : 24.
25. Arias-Pulido H, Narayan G, Vargas H, Mansukhani M, Murty V. Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions. Mol Cancer 2002 1 : 3.
26. Coe B, Henderson L, Garnis C et al. High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. Genes Chromosomes Cancer 2005 42 : 308 13.
27. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 2006 44 : 1755 62.
28. Pulido HA, Fakruddin MJ, Chatterjee A et al. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res 2000 60 : 6677 82.
29. Amann J, Kalyankrishna S, Massion PP et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005 65 : 226 35.
30. Arias-Pulido H, Joste N, Wheeler C. Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501- DQB1*0602 haplotype. Genes Chromosomes Cancer 2004 40 : 277 84.
31. Marchetti A, Martella C, Felicioni L et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005 23 : 857 65.
32. Qiulu P, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005 7 : 396 403.
33. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006 33 : 369 85.
34. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001 37 (Suppl. 4 S9 15.
35. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003 39 : 1348 54.
36. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002 55 : 244 65.
37. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993 67 : 4521 32.
38. Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005 24 : 2585 8.
39. Akerman GS, Tolleson WH, Brown KL et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res 2001 61 : 3837 43.
40. Sizemore N, Choo CK, Eckert RL, Rorke EA. Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells. Exp Cell Res 1998 244 : 349 56.
41. Hu G, Liu W, Mendelsohn J et al. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 1997 89 : 1271 6.
42. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004 109 : 157 62.
43. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005 97 : 339 46.
44. Lee JW, Soung YH, Kim SY et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 2005 113 : 510 1.
45. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004 351 : 2883.
46. Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers 2007 22 (Suppl. 4 S40 6.
47. Steiner P, Joynes C, Bassi R et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007 13 : 1540 51.
48. Bellone S, Palmieri M, Gokden M et al. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 2003 91 : 231 40.